Table 1.
Population, Treatment, and Outcome Characteristics Based on 3q Copy Number Status Assessed by Florescent in Situ Hybridization
| 3q Copy number | P value | |||
|---|---|---|---|---|
| Normal (2X) | Low-level amplification (3–4X copy number) | High-level amplification (>4X copy number) | ||
| Sample size, n (%) | 22 (44%) | 18 (36%) | 10 (20%) | — |
| Male gender, n (%) | 59% | 67% | 80% | NS* |
| Median age | 61.5 years | 64 years | 70 years | NS† |
| TNM stage, n (%) | NS‡ | |||
| I | 5 (23%) | 7 (39%) | 4 (40%) | |
| II | 6 (27%) | 3 (17%) | 2 (20%) | |
| III | 4 (18%) | 3 (17%) | 1 (10%) | |
| IV | 7 (32%) | 5 (28%) | 3 (30%) | |
| Tumor differentiation | NS† | |||
| Well | 2 (9%) | 0 | 2 (20%) | |
| Moderate | 19 (86%) | 17 (94%) | 7 (70%) | |
| Poor | 1 (5%) | 1 (6%) | 1 (10%) | |
| Extra nodal spread, n (%) | 1 (17%) | 5 (63%) | 2 (40%) | NS* |
| Anatomic location, n (%) | NS‡ | |||
| Oral cavity | 20 (91%) | 15 (83%) | 7 (70%) | |
| Larynx | 1 (4.5%) | 1 (6%) | 2 (20%) | |
| Oropharynx | 0 | 1 (6%) | 1 (20%) | |
| Hypopharynx | 1 (4.5%) | 1 (6%) | 0 | |
| Treatment, n (%) | NS‡ | |||
| Surgery | 15 (68%) | 11 (61%) | 6 (60%) | |
| Surgery and radiation | 6 (27%) | 6 (33%) | 3 (30%) | |
| Radiation | 1 (5%) | 3 (17%) | 1 (10%) | |
| Median follow-up, months | 54 | 90 | 115 | NS† |
| Locoregional recurrence | 7 (32%) | 13 (72%) | 9 (90%) | 0.003* |
| Death due to cancer | 3 (14%) | 8 (44%) | 7 (70%) | 0.006* |
| 3-year disease-free survival | 69.3% | 55.6% | 10% | 0.006§ |
| 3-year cause-specific survival | 93.8% | 83.0% | 40.0% | 0.001§ |
*Fisher’s exact test.
†Mann-Whitney U-test.
‡Chi-square test.
§Wilcoxon test for the comparison of Kaplan-Meier survival curves.